BMRA on Nasdaq
BIOMERICA INC
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Insight Molecular Diagnostics Inc., Anbio Biotechnology or Aspira Women's Health Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
8.1%Gross margin2
-119.5%Operating margin2
-84.8%Net margin2
-16.2%Revenue growth, 20262
-143.5%Return on equity2
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Clinical Lab brought in 61% of the revenue BIOMERICA INC broke down this way in fiscal 2026.
Products and services by year
| Products and services | 2025 | 2026 |
|---|---|---|
| Clinical Lab | $3.2M | $2.7M |
| Contract Manufacturing | $1.1M | $891.0K |
| Over-The-Counter | $1.0M | $821.0K |
| Physician?s office | $11.0K | $9.0K |
Regions
North America brought in 33% of the revenue BIOMERICA INC broke down this way in fiscal 2026.
Regions by year
| Regions | 2025 | 2026 |
|---|---|---|
| North America | $1.7M | $1.5M |
| Asia | $1.7M | $1.4M |
| Europe | $1.3M | $1.1M |
| Middle East | $630.0K | $446.0K |
| South America | $8.0K | $15.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2026
- Cost of revenue42¢$4.1M
- Research and development8¢$788.0K
- Selling, general and admin50¢$4.9M
- Income tax0¢$23.0K
Out of $4.5M in revenue.2 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-05-31 | 2025-05-31 |
|---|---|---|
| Net sales | $4.5M | $5.3M |
| Cost of sales | -$4.1M | -$4.8M |
| Gross profit | $362.0K | $498.0K |
| Selling, general and administrative | $4.9M | $4.6M |
| Research and development | $788.0K | $1.0M |
| Total operating expenses | $5.7M | $5.6M |
| Loss from operations | -$5.3M | -$5.1M |
| Dividend, interest, and other income | $1.2M | $165.0K |
| Unrealized holding gain on equity investment | $335.0K | |
| Total other income | $1.6M | $165.0K |
| Loss before income taxes | -$3.8M | -$5.0M |
| Provision for income taxes | -$23.0K | -$1.0K |
| Net loss | -$3.8M | -$5.0M |
| Basic net loss per common share | -$1.30 | -$2.16 |
| Diluted net loss per common share | -$1.30 | -$2.16 |
| Basic | 2.9M shares | 2.3M shares |
| Diluted | 2.9M shares | 2.3M shares |
| Foreign currency translation adjustment | -$3.0K | -$3.0K |
| Comprehensive loss | -$3.8M | -$5.0M |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-05-31 | 2025-11-30 | 2025-05-31 |
|---|---|---|---|
| Cash and cash equivalents | $1.3M | $2.4M | |
| Accounts receivable, net | $785.0K | $731.0K | |
| Inventories, net | $1.7M | $1.5M | |
| Prepaid expenses and other current assets | $216.0K | $255.0K | |
| Total current assets | $4.0M | $4.9M | |
| Property and equipment, net | $78.0K | $135.0K | |
| Right-of-use assets, net | $1.9M | $429.0K | |
| Investments | $500.0K | $165.0K | |
| Intangible assets, net of accumulated amortization of $89,000 and $69,000 as of May 31, 2026 and May 31, 2025, respectively | $209.0K | $228.0K | |
| Other assets | $83.0K | $113.0K | |
| Total Assets | $6.8M | $5.9M | |
| Accounts payable and accrued expenses | $1.2M | $672.0K | |
| Accrued compensation | $492.0K | $655.0K | |
| Advances from customers | $83.0K | $55.0K | |
| Lease liabilities, current portion | $235.0K | $358.0K | |
| Total current liabilities | $2.5M | $1.7M | |
| Lease liabilities, net of current portion | $1.6M | $100.0K | |
| Total Liabilities | $4.1M | $1.8M | |
| Common stock, $0.08 par value, 25,000,000 shares authorized as of May 31, 2026 and 2025, respectively, and 3,195,263 and 2,546,216 shares issued and outstanding as of May 31, 2026 and 2025, respectively | $255.0K | $203.0K | |
| Additional paid-in capital | $59.4M | $57.2M | |
| Accumulated other comprehensive loss | -$108.0K | -$105.0K | |
| Accumulated deficit | -$56.9M | -$53.2M | |
| Total shareholders equity | $2.6M | $4.1M | |
| Total Liabilities and Shareholders Equity | $6.8M | $5.9M | |
| Accumulated amortization | $89.0K | $69.0K | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 4.4M shares | 5.0M shares | 4.4M shares |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.08 | $0.08 | |
| Common stock, shares authorized | 25.0M shares | 300.0M shares | 25.0M shares |
| Common stock, shares issued | 3.2M shares | 2.5M shares | |
| Common stock, shares outstanding | 3.2M shares | 2.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-05-31 | 2025-05-31 |
|---|---|---|
| Net loss | -$3.8M | -$5.0M |
| Depreciation and amortization | $77.0K | $87.0K |
| Provision for allowance for credit losses | $12.0K | $8.0K |
| (Recovery) provision for inventory reserves | -$77.0K | $4.0K |
| Share-based compensation | $476.0K | $460.0K |
| Amortization of right-of-use asset | $344.0K | $313.0K |
| Unrealized holding gain on equity investment | -$335.0K | |
| Accounts receivable | -$66.0K | $209.0K |
| Inventories | -$140.0K | $882.0K |
| Prepaid expenses and other current assets | $39.0K | -$17.0K |
| Other assets | $23.0K | $9.0K |
| Accounts payable and accrued expenses | $499.0K | -$467.0K |
| Accrued compensation | -$163.0K | |
| Advances from customers | $28.0K | -$30.0K |
| Reduction in lease liabilities | -$363.0K | -$327.0K |
| Net cash used in operating activities | -$3.4M | -$3.8M |
| Expenditures related to intangibles | -$1.0K | -$37.0K |
| Net cash used in investing activities | -$1.0K | -$37.0K |
| Gross proceeds from sale of common stock | $1.9M | $2.1M |
| Deferred offering costs | -$3.0K | |
| Costs from sale of common stock | -$40.0K | -$44.0K |
| Proceeds from exercise of stock options | $15.0K | |
| Proceeds from secured promissory note payable related party | $500.0K | |
| Net cash provided by financing activities | $2.3M | $2.1M |
| Effect of exchange rate changes on cash | -$3.0K | -$3.0K |
| Net decrease in cash and cash equivalents | -$1.1M | -$1.8M |
| Income taxes | $22.0K | $10.0K |
| Deferred offering costs | $7.0K | $84.0K |
| Right-of-use assets obtained in exchange for operating lease liabilities | $1.8M | |
| Write-off of fully depreciated property and equipment | $14.0K |
Recent filings
- Oct 7, 2026EFFECT
- Oct 7, 2026EFFECT
- Sep 28, 202610-K/A
- Sep 24, 2026S-3
- Sep 24, 2026S-3
- Sep 8, 20263
- Aug 31, 202610-K
- Aug 27, 20264
- Aug 27, 20264
- Aug 27, 20264
- Aug 27, 20264
- Aug 27, 20264
- Aug 26, 20268-K
- Jun 4, 20268-K
- Apr 13, 202610-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBIOMERICA INC filings on SEC EDGAR
- 2SEC EDGARBIOMERICA INC 10-K for fiscal 2026
- 3SEC EDGARBIOMERICA INC filings on SEC EDGAR
- 4SEC EDGARBIOMERICA INC 10-K for fiscal 2019
- 5SEC EDGARBIOMERICA INC 10-K for fiscal 2020
- 6SEC EDGARBIOMERICA INC 10-K for fiscal 2021
- 7SEC EDGARBIOMERICA INC 10-K for fiscal 2022
- 8SEC EDGARBIOMERICA INC 10-K for fiscal 2023
- 9SEC EDGARBIOMERICA INC 10-K for fiscal 2024
- 10SEC EDGARBIOMERICA INC 10-Q for fiscal 2025
- 11SEC EDGARBIOMERICA INC 10-Q for fiscal 2026